FDA selects flu strains for next round of vaccines

The FDA has come up with a lineup of three all-new flu strains for this year's vaccine recipe. Typically, only one or two strains are changed, but health officials felt that following last season's ineffective vaccine jab a new approach was called for.

It's not easy getting the strains right. Most vaccines are consistently effective against their targets. But the steadily changing nature of influenza makes it a tough target to hit. Inevitably, there's always a guessing game about which strains will be circulating during an upcoming flu season.

This season's list of manufacturers and approved vaccines (by way of the Washington Post): CSL Limited, Afluria; GlaxoSmithKline Biologicals, Fluarix; ID Biomedical, FluLaval; MedImmune Vaccines, FluMist; Novartis Vaccines and Diagnostics, Fluvirin; and Sanofi Pasteur, Fluzone.

- read the story from the Washington Post

Suggested Articles

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.

Shingrix sales in the second quarter plummeted by half from first-quarter levels, and recovery of vaccination rates remains slow amid the pandemic.